1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF103659, NCT00338247
|
|
2.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: GEICAM/2006-14, Nº EudraCT 2007-007031-13, NCT00841828
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GSK-EGF30008, UCLA-0311034-01, NCT00073528
|
|
4.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF104383, NCT00272987
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40302, NCT00390455
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: EGF102988, NCT00424255
|
|
7.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NSABP B-41, NCT00486668
|
|
8.
|
Phase: Phase III Type: Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 104578, NCT00486954
|
|
9.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: EGF106708, BIG 2-06/N063D/MAC13, NCT00490139
|
|
10.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF106903, BIG 1-06, NCT00553358
|
|
11.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG108838, NCT00558103
|
|
12.
|
Phase: Phase III Type: Genetics, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GBG 44, EudraCT No.: 2006-005834-19, NCT00567554
|
|
13.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CAN-NCIC-MA31, MA31, GSK-EGF108919, EUDRACT-2007-004568-27, NCT00667251
|
|
14.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GIM-GIM8-OVER, GIM8-OVER, EUDRACT-2007-006031-30, EU-20853, GSK-GIM-GIM8-OVER, ZENECA-GIM-GIM8-OVER, OVER, NCT00688194
|
|
15.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF110656, EGF110656-TRIO-CIRG 013, NCT00680901
|
|
16.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40601, CALGB 40601, NCT00770809
|
|
17.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3144A2-3003, NCT00777101
|
|
18.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TDM4370g, 2008-005 713-22, NCT00829166
|
|
19.
|
Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111438, NCT00820222
|
|
20.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: EORTC-10054, GSK-EORTC-10054, EUDRACT-2006-000864-94, NCT00450892
|
|
21.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: INST 0514C, NCT00455039
|
|
22.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and over Sponsor: NCI Protocol IDs: BCM-H-19895, H-19895, BCM-P50-CA-58183, NCT00555152
|
|
23.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3144A1-2206, NCT00741260
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: WSU-C-2876, 6724, NCI-6724, NCT00118157
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: D-0520, NCT00225758
|